CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
CRISPR Therapeutics announced that its senior management team will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, at 2:15 p.m. ET. A live webcast of the fireside chat will be available on the Investors section of the company's website, with a replay archived for 14 days. CRISPR Therapeutics is a biopharmaceutical company focused on gene-based medicines, known for CASGEVY®, the first CRISPR-based therapy for sickle cell disease and beta thalassemia.
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know
The article states that CRISPR Therapeutics AG (CRSP) is drawing investor interest. It advises readers to understand what is happening with the company. The rest of the content is missing.
Genome Editing Market Is Going to Boom |• CRISPR Therapeutics • Editas Medicine
Worldwide Market Reports has published a comprehensive analysis titled "Genome Editing Market Size and Forecast 2026-2033," predicting significant growth in the genome editing sector. The report, based on extensive research, details market drivers, challenges, opportunities, and competitive landscapes, featuring key players like CRISPR Therapeutics and Editas Medicine. It offers crucial insights for stakeholders, covering market segmentation by types and applications, regional trends, and forecasts to aid investment decisions.
CRISPR Therapeutics AG (CRSP) stock price, news, quote and history
This page provides comprehensive information on CRISPR Therapeutics AG (CRSP), a gene-editing company. It includes real-time stock price data, historical performance, key financial metrics, analyst insights, and comparisons with similar biotechnology firms. The company specializes in gene-based medicines using its CRISPR/Cas9 platform, with lead product CASGEVY for blood disorders and various CAR T-cell therapies in development.
Assessing CRISPR Therapeutics (CRSP) Valuation As Casgevy Revenue And Cash Position Support Its Growth Transition
CRISPR Therapeutics (CRSP) is gaining investor attention after its gene-editing therapy, Casgevy, started generating commercial revenue, supported by Vertex Pharmaceuticals and a strong cash position for future trials. Despite a recent short-term dip, the stock is up significantly over the past year. While its price-to-book ratio is slightly above the industry average, a Discounted Cash Flow (DCF) model suggests the stock is significantly undervalued, trading 73.9% below the estimated future cash flow value of $189.74.
CRISPR Therapeutics AG (CRSP) Stock Price, News, Quote & History
This article provides a comprehensive overview of CRISPR Therapeutics AG (CRSP) stock, including its current price, historical performance, key financial metrics, and recent news. It details the company's focus on gene editing using its CRISPR/Cas9 platform to develop gene-based medicines for various serious human diseases, highlighting its lead product candidate CASGEVY and other pipeline programs. The report also includes analyst insights and comparisons with similar biotechnology companies.
CRISPR Therapeutics AG (CRSP) Outperforms the Market: Key Points to Note
CRISPR Therapeutics AG (CRSP) saw a 2.61% increase in its latest trading session, outperforming the broader market despite a significant decline over the past month. The company is poised to release its earnings, with estimates suggesting substantial year-over-year revenue growth. Analysts are closely watching forecast revisions, which currently place CRSP with a Zacks Rank of #3 (Hold).
Mizuho Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
Mizuho Securities has reaffirmed its Buy rating on Crispr Therapeutics AG (CRSP) with an $85.00 price target. This comes despite a mixed analyst sentiment, as Piper Sandler also issued a Buy, while TipRanks – xAI reiterated a Hold rating. The company recently reported a quarterly GAAP net loss of $130.61 million, and corporate insider sentiment is positive with increased insider buying activity.
Return on equity % of CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh – SET:CRSP03
This article concerns the Return on Equity (%) for CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh (SET:CRSP03). It presents financial data for the specified period, noting the value, change, and change percentage. The content is primarily a listing of financial data categories for the company.
Why CRISPR Therapeutics AG (CRSP) outpaced the stock market today
This article states that CRISPR Therapeutics AG (CRSP) outperformed the stock market today. No further details are provided regarding the reasons for this outperformance.
Truist Financial Upgrades CRISPR Therapeutics (NASDAQ:CRSP) to "Strong-Buy"
Truist Financial has upgraded CRISPR Therapeutics (NASDAQ:CRSP) to a "Strong-Buy" rating, joining other analysts with bullish outlooks despite a recent earnings miss and a 97.8% year-over-year revenue decline. The stock maintains a consensus "Moderate Buy" rating with a $64.53 price target, although significant insider selling has occurred recently. Analysts cite pipeline optimism as a key factor for the continued positive ratings.
CRISPR Therapeutics AG (CRSP) is a trending stock: Facts to know before betting on it
The article discusses CRISPR Therapeutics AG (CRSP) as a trending stock, providing essential information investors should consider before making a decision. It highlights key facts that could influence its stock performance.
Why CRISPR Therapeutics AG (CRSP) Performed Better Than the Market Today
CRISPR Therapeutics AG (CRSP) outperformed the broader market, rising 1.42% while the S&P 500, Dow, and Nasdaq saw smaller gains. Despite a recent monthly decline, investors are anticipating strong upcoming earnings with projected year-over-year EPS and revenue improvements. The company's stock currently holds a Zacks Rank of #3 (Hold) within the Medical - Biomedical and Genetics sector.
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today
CRISPR Therapeutics AG (CRSP) shares rose 1.42% to $47.09, outperforming the broader market. This comes despite an 18.21% drop in the past month for the company, while the Medical sector lost 8.43%. Investors are looking forward to the upcoming earnings report, with an anticipated EPS increase of 27.22% and a significant revenue jump of 741.03% compared to the prior year.
CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 3,182 Shares
CRISPR Therapeutics General Counsel James Kasinger sold 3,182 shares of the company's stock for approximately $148,854, reducing his stake by 3.26%. This sale comes as the company reported an earnings and revenue miss, with EPS of ($1.37) against an expected ($1.15) and revenue significantly below estimates. Analysts currently have a "Hold" rating on CRISPR Therapeutics with a consensus price target of $64.53, despite a mix of Buy, Hold, and Sell recommendations.
CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells 10,020 Shares
CRISPR Therapeutics CEO Samarth Kulkarni sold 10,020 shares of the company's stock on March 23rd for approximately $468,736, reducing his holding by 3.77%. This is part of an ongoing trend, as Kulkarni has sold a total of 127,134 shares this year across six transactions, generating about $7.02 million. The company recently reported weaker-than-expected Q4 earnings, missing EPS and revenue estimates, and currently holds a consensus "Hold" rating from analysts.
CRISPR Therapeutics (CRSP) CEO gets major equity awards, sells shares for taxes
CRISPR Therapeutics CEO Samarth Kulkarni received significant equity awards, including a stock option for 114,249 common shares and 81,875 new restricted stock units, and also had 19,687 restricted stock units vest. Concurrently, Kulkarni sold 10,020 common shares for $46.78 each to cover tax withholding obligations associated with the RSU vesting, as per company policy. After these transactions, Kulkarni holds 255,501 common shares directly, with some still under a lock-up agreement.
CRISPR (CRSP) GC granted options, RSUs; sells shares for taxes
CRISPR Therapeutics AG General Counsel James R. Kasinger received new equity awards, including a stock option for 38,499 common shares and 25,000 Restricted Stock Units (RSUs) with multi-year vesting schedules. He also sold 3,182 common shares at $46.78 each to cover tax withholding obligations associated with the vesting of prior RSU grants, a non-discretionary transaction. After these activities, Kasinger directly holds 94,308 common shares, which remain subject to a lock-up agreement.
Crispr Therapeutics Insider Sold Shares Worth $468,736, According to a Recent SEC Filing
An insider at Crispr Therapeutics AG has sold shares valued at $468,736, as revealed in a recent SEC filing. The company, a Switzerland-based gene editing firm focused on CRISPR/Cas9-based therapeutics, has been active with various corporate announcements, including convertible notes offerings and earnings reports. CRISPR Therapeutics AG aims to apply its gene-editing technology to treat genetically-defined diseases and engineer advanced cellular therapies.
[Form 4] CRISPR Therapeutics AG Insider Trading Activity
CRISPR Therapeutics AG's CFO, Prasad Raju, disclosed recent equity transactions including the receipt of stock options and restricted stock units (RSUs). He also reported a sale of 3,708 common shares on March 23, 2026, at an average price of $46.78, which was specifically to cover tax withholding obligations associated with RSU vesting rather than being a discretionary trade. Following these transactions, Raju directly holds 15,565 common shares, subject to a lock-up agreement related to the issuer’s convertible senior notes due 2031.
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Hold" from Analysts
CRISPR Therapeutics AG (NASDAQ:CRSP) has received a consensus "Hold" rating from 18 analysts, with an average one-year price target of $64.53. While CASGEVY patient starts have nearly tripled year-over-year and CTX310 shows promise, the company faces financial risks including recent convertible note issuance causing dilution risk, missed EPS and revenue expectations, and insider stock sales. Investors are awaiting further clinical readouts for its early-stage pipeline.
JPMorgan Chase & Co. Has $38.46 Million Holdings in CRISPR Therapeutics AG $CRSP
JPMorgan Chase & Co. significantly increased its stake in CRISPR Therapeutics AG ($CRSP) by 98.3% in Q3, now holding 593,416 shares valued at $38.46 million. Despite this, CRISPR Therapeutics recently reported a wider-than-expected EPS miss and a substantial revenue decline, and while positive sentiment exists around its CASGEVY therapy and pipeline, concerns remain about pipeline uncertainty and potential share dilution from a recent $550 million convertible note. The company's stock has a "Hold" consensus rating from analysts with an average target price of $64.53.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
This article from MSN reports that CRISPR Therapeutics AG (CRSP) stock experienced a decline even as the broader market saw gains. The brief title suggests investors may want to understand the factors behind CRSP's underperformance in a rising market.
CRISPR Therapeutics AG (CRSP) Declines Sharply Compared to Overall Market: Essential Information for Investors
CRISPR Therapeutics AG (CRSP) experienced a sharp decline of 4.79% in its stock price, underperforming key market indices like the S&P 500, Dow Jones, and Nasdaq. Despite the recent dip, analysts project significant year-over-year revenue growth of 741.03% for the upcoming quarter and over 1000% for the full fiscal year, alongside improved earnings. The company currently holds a Zacks Rank of #3 (Hold) within the Medical - Biomedical and Genetics industry.
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
This article will likely discuss reasons why CRISPR Therapeutics AG (CRSP) stock is currently trending. It will aim to provide insights beyond just its popularity, potentially covering fundamental analysis, recent news, or future prospects for the company.
CRISPR Therapeutics AG (CRSP) Declines Sharply Compared to Overall Market: Essential Information for Investors
CRISPR Therapeutics AG (CRSP) experienced a sharp decline in its stock performance, falling 4.79% in the latest trading session, which was steeper than the overall market decline. The company is approaching its next earnings report, with analysts forecasting a significant improvement in year-over-year earnings and revenue. Investors are advised to monitor analyst revisions and consider the company's Zacks Rank of #3 (Hold) within its industry.
CRISPR Therapeutics AG Bonds — Corporate Bond Rates
This article lists the corporate bond rates for CRISPR Therapeutics AG (CRSP) as of its publication. It highlights one specific bond: US226712AA5 CRISPR Therapeutics AG 1.125% 01-MAR-2031, which has a coupon of 1.125% and an outstanding amount of 550 million USD. The piece emphasizes that bonds can offer increased stability for investors during volatile market conditions.
Crispr Therapeutics Completes $600 Million Convertible Notes Offering
CRISPR Therapeutics AG successfully completed a $600 million private offering of Convertible Senior Notes due 2031, which included a $50 million option exercise, generating net proceeds of approximately $585.2 million for corporate purposes. The notes, maturing on March 1, 2031, are convertible into common shares at a 45% premium. Despite this financing, TipRanks' AI Analyst, Spark, rates CRSP as Neutral due to volatile revenue, persistent losses, cash burn, and weak technical signals, although recent pipeline progress offers some support.
CRISPR Therapeutics (CRSP) Is Down 5.1% After $550M Convertible Notes Offering - Has The Bull Case Changed?
CRISPR Therapeutics' stock dropped 5.1% after a US$550 million convertible notes offering, which extends its funding runway for gene-editing programs but doesn't fundamentally alter its high-risk, high-reward investment profile. The company's future success heavily depends on clinical trial readouts and regulatory progress, and while the offering provides financial flexibility, varied fair value estimates among analysts highlight the speculative nature of the investment.
CRISPR Therapeutics (CRSP) Is Down 5.1% After $550M Convertible Notes Offering - Has The Bull Case Changed?
CRISPR Therapeutics (CRSP) recently completed a US$550 million convertible notes offering to strengthen its balance sheet and support ongoing gene-editing programs. While this financing extends the company's funding runway and supports its long-term investment narrative, the short-term catalysts remain clinical readouts and regulatory progress. The stock saw a 5.1% drop after the announcement, and its fair value remains a subject of wide debate given its current high-risk, high-conviction profile.
CRISPR Therapeutics (NASDAQ:CRSP) Insider Naimish Patel Sells 3,150 Shares of Stock
CRISPR Therapeutics (NASDAQ:CRSP) insider Naimish Patel sold 3,150 shares of the company's stock for $152,019, reducing his stake by 19.33%. The sale occurred on March 16th at an average price of $48.26 per share. This comes as the company faces mixed fundamentals, having missed quarterly EPS estimates and reported a significant revenue drop, although analysts' consensus is a "Hold" with a target price of $64.53.
Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells 10,349 Shares of Stock
CRISPR Therapeutics CEO Samarth Kulkarni sold 10,349 shares of CRSP stock on March 16th for approximately $499,443, reducing his stake by 4.04%. This sale is part of a pattern of insider selling, with Kulkarni having sold over 100,000 shares this year. The company recently reported disappointing Q4 earnings, missing analyst estimates for both EPS and revenue, though analysts maintain a consensus "Hold" rating with a target price of $64.53.
CRISPR Therapeutics (NASDAQ: CRSP) CMO vests RSUs, mandated tax sale
CRISPR Therapeutics AG's Chief Medical Officer, Naimish Patel, reported the vesting of 8,125 Restricted Stock Units (RSUs) on March 14, 2026, which converted into common shares. Concurrently, 3,150 common shares were sold at $48.26 each on March 16, 2026, to cover tax withholding obligations as mandated by the company's RSU Settlement Policy, a non-discretionary transaction. Following these transactions, Patel directly holds 13,143 common shares and retains 24,375 unvested RSUs.
CRISPR Therapeutics (NASDAQ: CRSP) GC sells shares for tax withholding
CRISPR Therapeutics General Counsel and Secretary James R. Kasinger reported RSU vesting and a subsequent sale of shares to cover tax withholding obligations. On March 14, 2026, 6,875 restricted stock units converted into common shares, and on March 16, 2026, Kasinger sold 3,450 common shares at $48.26 each for tax purposes, as mandated by the company's RSU Settlement Policy. Following these transactions, Kasinger directly holds 91,240 common shares and 20,625 RSUs, with remaining shares subject to a lock-up agreement.
CRISPR Therapeutics (CRSP) CEO logs RSU vesting and tax-driven share sale
CRISPR Therapeutics (CRSP) CEO Samarth Kulkarni reported the vesting of 20,625 Restricted Stock Units (RSUs) on March 14, 2026. To cover tax withholding obligations associated with this vesting, 10,349 common shares were sold at $48.26 each, a transaction mandated by the company's RSU Settlement Policy rather than a discretionary sale. Following these transactions, Kulkarni directly holds 245,834 common shares and 61,875 RSUs.
Goodwin Guides CRISPR Therapeutics On Pricing $550 Million Upsized Convertible Senior Notes Offering
Goodwin Procter LLP guided CRISPR Therapeutics AG on the pricing of an upsized $550 million convertible senior notes offering due 2031. CRISPR Therapeutics, a leading biopharmaceutical company known for its CRISPR-based therapy CASGEVY®, plans to use the funds to advance its diversified pipeline of gene-based medicines. The offering, initially announced for $350 million, was increased due to strong demand.
CRISPR Therapeutics (NASDAQ:CRSP) Receives Overweight Rating from Piper Sandler
Piper Sandler reiterated an "Overweight" rating for CRISPR Therapeutics (CRSP), raising its price target to $110, which implies a potential 123.71% upside. This comes despite CRISPR reporting weaker-than-expected quarterly results and notable insider selling. Currently, analysts have a mixed view with an average "Hold" rating and an average target price of $64.53.
Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now?
The article discusses Crispr Therapeutics (CRSP) as a top gene-editing stock, highlighting its FDA-approved CASGEVY therapy, strong pipeline, and increased hedge fund sentiment. It notes that the company's shares are up 16% over the past year, with Cathie Wood's ARK increasing its stake. The article also touches on the significant market opportunity for Casgevy, especially given its one-time treatment nature and partnership with Vertex Pharmaceuticals.
CRISPR Therapeutics AG Experiences Revision in Stock Evaluation Amid Market Dynamics
CRISPR Therapeutics AG's stock evaluation has been revised due to recent fluctuations and mixed technical indicators. The company, currently trading at $48.75, has shown challenges compared to the S&P 500, particularly in its long-term performance despite a 16.10% return over the past year. Technical analyses, including MACD and Bollinger Bands, present a mixed outlook, indicating a lack of strong directional movement.
Clough Capital Partners L P Makes New $1.49 Million Investment in CRISPR Therapeutics AG $CRSP
Clough Capital Partners L P has made a new $1.49 million investment in CRISPR Therapeutics AG, acquiring 23,000 shares in the third quarter. This comes amidst selling pressure on CRISPR Therapeutics following a $550M convertible notes deal and insider sales, including 111,677 shares worth $6.31M by insiders in the last quarter. The company also reported an earnings miss and a significant year-over-year revenue decline, indicating near-term challenges.
CRISPR Therapeutics’ CASGEVY Progress Reframes Growth And Valuation Story
CRISPR Therapeutics (NasdaqGM:CRSP) is transitioning into a commercial-stage company due to the strong progress of its gene-editing therapy, CASGEVY, which has shown higher-than-expected revenue contribution and a threefold increase in projected patient initiations for 2025. Despite being unprofitable with a significant net loss, the company's valuation is seen as undervalued by Simply Wall St, and its stock has experienced renewed investor interest. The future growth depends on CASGEVY's continued adoption and the advancement of its clinical pipeline.
Assessing CRISPR Therapeutics (CRSP) Valuation After Upsized US$550m Convertible Notes Offering
CRISPR Therapeutics (CRSP) recently completed an upsized US$550 million convertible senior notes offering, drawing attention to its funding amid a weak share performance. Despite a recent share price decline, the company's valuation, using a Price-to-Book (P/B) ratio of 2.5x and a Discounted Cash Flow (DCF) model, suggests it is undervalued compared to peers and its intrinsic value. However, the analysis also notes ongoing net losses and regulatory risks for programs like CASGEVY.
CRISPR Therapeutics (CRSP) CEO RSU vesting and 9,798-share tax sale
CRISPR Therapeutics CEO Samarth Kulkarni reported the vesting of 19,250 restricted stock units on March 10, 2026. Following this, 9,798 common shares were sold on March 11, 2026, at $52.80 per share to cover tax withholding obligations in accordance with the company's RSU Settlement Policy. After these transactions, Kulkarni directly held 235,558 common shares, indicating the sale was non-discretionary and purely for tax purposes.
Assessing CRISPR Therapeutics (CRSP) Valuation After Upsized US$550m Convertible Notes Offering
CRISPR Therapeutics (CRSP) recently completed an upsized US$550 million convertible senior notes offering, drawing attention to its valuation amidst a recent share price decline. Despite short-term drops, the company's 2.5x Price-to-Book ratio and a Discounted Cash Flow model suggest it is undervalued, with an estimated intrinsic value of $190.99 compared to its current trading price of $49.93. Investors are cautioned to consider clinical setbacks and ongoing losses, even as revenue is projected to grow significantly.
CRISPR Therapeutics AG (CRSP) Falls Sharper Than Overall Market: Key Information to Note
CRISPR Therapeutics AG (CRSP) experienced a 5.44% stock price fall, closing at $49.93, a sharper decline than the S&P 500. Despite this recent dip, the company had previously outperformed both the Medical sector and the S&P 500. Investors are now anticipating CRISPR Therapeutics' upcoming earnings report, with analysts expecting significant improvements in EPS and revenue compared to the previous year.
CRISPR Therapeutics (NASDAQ: CRSP) prices $550M 2031 convertible notes
CRISPR Therapeutics (NASDAQ: CRSP) has priced an upsized private offering of $550 million in aggregate principal amount of convertible senior notes due 2031. The offering, sold to qualified institutional buyers, has an effective coupon of 1.125% (increasing to 1.7308% to offset Swiss withholding tax) and an initial conversion price of approximately $76.56 per share, representing a 45% premium over the March 10, 2026, stock price. The company expects to receive approximately $536.3 million in net proceeds, or $585.2 million if the purchasers' option is fully exercised, slated for general corporate purposes.
Capital International Investors Acquires 55,511 Shares of CRISPR Therapeutics AG $CRSP
Capital International Investors increased its stake in CRISPR Therapeutics AG by 1.0%, acquiring an additional 55,511 shares to own 5,649,258 shares, valued at approximately $366.13 million. This increase occurred despite a proposed offering of convertible senior notes and recent financial misses that caused the stock to drop. Institutional ownership remains high at about 69.2%, with several large funds increasing their positions, while insiders have sold a significant number of shares.
Crispr Therapeutics Upsizes Convertible Notes Offering to $550 Million
CRISPR Therapeutics initially launched a private $350 million convertible notes offering on March 10, 2026. Due to strong investor demand, the company upsized the offering to $550 million on March 11, 2026, to strengthen its financial flexibility and support its gene-editing programs. TipRanks' AI Analyst, Spark, rates CRSP as "Neutral" due to weak financial performance and a bearish technical setup, despite a strong balance sheet and positive pipeline updates.
CRISPR Therapeutics AG Prices $550 Million Convertible Senior Notes Offering Due 2031
CRISPR Therapeutics AG has priced a $550 million private offering of convertible senior notes due in 2031, upsized from an initial $350 million, with proceeds for general corporate purposes. The notes carry a coupon rate of 1.125% (adjusted to 1.7308% due to Swiss tax withholding) and can be converted into common shares at approximately $76.56 per share. The offering is expected to close on March 16, 2026, providing significant capital to advance the company's gene-editing platform.
Cathie Wood buys the dip in gene-editing firm CRISPR Therapeutics (CRSP:NASDAQ)
Cathie Wood's ARK Invest has bought a significant stake in gene-editing firm CRISPR Therapeutics (CRSP) by purchasing over 280,000 shares worth approximately $14.82 million. This move is part of ARK Invest's strategy to add to beaten-down technology and biotech names, while trimming other positions.
